Overall, notwithstanding some heterogeneity between patients, our data shows that Phospho-Plus Variant 4 can be seeded by PSP-tau, suggesting that the phosphorylation sites contained in this variant potentially differentiate PSP and AD seeding susceptibility, with phosphorylation mimics in this construct inhibiting AD-tau seeding consistently. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.